Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study.

被引：0
|
作者：
Sunkureddi, P. [1 ]
Toth, E. [2 ]
Brown, J. P. [3 ,4 ]
Moericke, R. [5 ]
Richard, D. [6 ]
Lheritier, K. [6 ]
Stancati, A. [6 ]
Kivitz, A. [7 ]
机构：
[1] Clear Lake Rheumatol, Nassau Bay, TX USA
[2] Flor Francis Hosp, Dept Rheumatol, Kistarcsa, Hungary
[3] CHU Quebec, Res Ctr, Quebec City, PQ, Canada
[4] Univ Laval, Quebec City, PQ, Canada
[5] Inst Pravent Med & Klin Forsch GbR, Magdeburg, Germany
[6] Novartis Pharma AG, Basel, Switzerland
[7] Altoona Ctr Clin Res, Duncansville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
    Buch, M. H.
    Aletaha, D.
    Caporali, R.
    Combe, B.
    Schulze-Koops, H.
    Gottenberg, J. E.
    Tanaka, Y.
    Blanco, R.
    Takeuchi, T.
    Omoruyi, E. V. Ekoka
    Van Beneden, K.
    Rajendran, V.
    Watson, C.
    De Leonardis, F.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 729 - 730
  • [22] Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
    Wilcock, G
    Truyen, L
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S119 - S119
  • [23] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [24] Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study
    Iwata, Naomi
    Nishimura, Kenichi
    Hara, Ryoki
    Imagawa, Tomoyuki
    Shimizu, Masaki
    Tomiita, Minako
    Umebayashi, Hiroaki
    Takei, Syuji
    Seko, Noriko
    Wakabayashi, Ryota
    Yokota, Shumpei
    MODERN RHEUMATOLOGY, 2023, 33 (06) : 1162 - 1170
  • [25] Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up.
    Schlesinger, Naomi
    Alten, Rieke
    Bardin, Thomas
    Schumacher, H. Ralph, Jr.
    Bloch, Mark
    Lheritier, Karine
    Richard, Dominik
    Stancati, Andrea
    So, Alexander
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S66 - S67
  • [26] Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients
    Nishimura, Kenichi
    Hara, Ryoki
    Umebayashi, Hiroaki
    Takei, Syuji
    Iwata, Naomi
    Imagawa, Tomoyuki
    Shimizu, Masaki
    Tomiita, Minako
    Seko, Noriko
    Kitawaki, Tetsuji
    Yokota, Shumpei
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 226 - 234
  • [27] LONG-TERM SAFETY AND EFFICACY OF CANAKINUMAB IN PATIENTS WITH CAPS: FINAL RESULTS FROM THE BETA-CONFIDENT REGISTRY
    Kuemmerle-Deschner, J. B.
    Hoffman, H.
    Hawkins, P. N.
    van der Poll, T.
    Walker, U. A.
    Speziale, A.
    Tilson, H. H.
    Joubert, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 617 - 617
  • [28] Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Hu, Xueqiang
    Xu, Xianhao
    Lublin, Alex L.
    Truffinet, Philippe
    Chavin, Jeffrey
    Delhay, Jean-Luc
    Benamor, Myriam
    Purvis, Annie
    Freedman, Mark S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [29] Efficacy of Canakinumab on Re-Treatment in Gouty Arthritis Patients with Limited Treatment Options: 24-Week Results From β-RELIEVED and β-RELIEVED-II Studies.
    Alten, R.
    So, A.
    Kivitz, A.
    Bardin, T.
    Bloch, M.
    Gimona, A.
    Widmer, A.
    Krammer, G.
    Schlesinger, N.
    Schumacher, H. R.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S402 - S402
  • [30] Safety and Efficacy of Long-Term Canakinumab Therapy in Patients with CAPS: Final Results from Beta-Confident Registry
    Hoffman, Hal M.
    Kuemmerle-Deschner, Jasmin B.
    Hawkins, Philip N.
    van der Poll, Tom
    Walker, Ulrich A.
    Speziale, Antonio
    Joubert, Yolandi
    Tilson, Hugh H.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345